Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2020
This article has no abstract
Epistemonikos ID: b36eb6a123a203eb00294e4e0c62d44117730a87
First added on: Feb 06, 2026